JP2017504586A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017504586A5 JP2017504586A5 JP2016538593A JP2016538593A JP2017504586A5 JP 2017504586 A5 JP2017504586 A5 JP 2017504586A5 JP 2016538593 A JP2016538593 A JP 2016538593A JP 2016538593 A JP2016538593 A JP 2016538593A JP 2017504586 A5 JP2017504586 A5 JP 2017504586A5
- Authority
- JP
- Japan
- Prior art keywords
- amd
- binding portion
- monoclonal antibody
- binds
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003197 catalytic effect Effects 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 241000191940 Staphylococcus Species 0.000 claims description 11
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 8
- 210000002421 cell wall Anatomy 0.000 claims description 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 6
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 6
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 6
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 6
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 6
- 108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 claims description 6
- 102100030397 N-acetylmuramoyl-L-alanine amidase Human genes 0.000 claims description 6
- 241000191984 Staphylococcus haemolyticus Species 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 241001147693 Staphylococcus sp. Species 0.000 claims description 5
- 241001147695 Staphylococcus caprae Species 0.000 claims description 4
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 4
- 229940037649 staphylococcus haemolyticus Drugs 0.000 claims description 4
- 108700023418 Amidases Proteins 0.000 claims description 3
- 102000005922 amidase Human genes 0.000 claims description 3
- 101150007054 AMD1 gene Proteins 0.000 claims description 2
- 101150067537 AMD2 gene Proteins 0.000 claims description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- 241001147691 Staphylococcus saprophyticus Species 0.000 claims description 2
- 229960003767 alanine Drugs 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 description 59
- -1 ceftbiprole Chemical compound 0.000 description 12
- 239000002955 immunomodulating agent Substances 0.000 description 12
- 239000007943 implant Substances 0.000 description 12
- 230000003115 biocidal effect Effects 0.000 description 9
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 8
- 229960002227 clindamycin Drugs 0.000 description 8
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 230000000399 orthopedic effect Effects 0.000 description 7
- 241000295644 Staphylococcaceae Species 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 206010041925 Staphylococcal infections Diseases 0.000 description 5
- 108010059993 Vancomycin Proteins 0.000 description 5
- 206010000269 abscess Diseases 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229960003165 vancomycin Drugs 0.000 description 5
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 5
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 5
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 4
- 108010013198 Daptomycin Proteins 0.000 description 4
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 4
- 229930182566 Gentamicin Natural products 0.000 description 4
- 108010000540 Hexosaminidases Proteins 0.000 description 4
- 102000002268 Hexosaminidases Human genes 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- PPKJUHVNTMYXOD-PZGPJMECSA-N c49ws9n75l Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O PPKJUHVNTMYXOD-PZGPJMECSA-N 0.000 description 4
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 4
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 4
- 229960001139 cefazolin Drugs 0.000 description 4
- 229940036735 ceftaroline Drugs 0.000 description 4
- ZCCUWMICIWSJIX-NQJJCJBVSA-N ceftaroline fosamil Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OCC)C=2N=C(NP(O)(O)=O)SN=2)CC=1SC(SC=1)=NC=1C1=CC=[N+](C)C=C1 ZCCUWMICIWSJIX-NQJJCJBVSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229940047766 co-trimoxazole Drugs 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 229960002488 dalbavancin Drugs 0.000 description 4
- 108700009376 dalbavancin Proteins 0.000 description 4
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 4
- 229960005484 daptomycin Drugs 0.000 description 4
- 229960003276 erythromycin Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229960004675 fusidic acid Drugs 0.000 description 4
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 4
- 229960002518 gentamicin Drugs 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 4
- 229960003907 linezolid Drugs 0.000 description 4
- 229960004023 minocycline Drugs 0.000 description 4
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229960001607 oritavancin Drugs 0.000 description 4
- VHFGEBVPHAGQPI-MYYQHNLBSA-N oritavancin Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(NCC=4C=CC(=CC=4)C=4C=CC(Cl)=CC=4)C2)OC2=CC=C(C=C2Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 VHFGEBVPHAGQPI-MYYQHNLBSA-N 0.000 description 4
- 108010006945 oritavancin Proteins 0.000 description 4
- 108010071077 quinupristin-dalfopristin Proteins 0.000 description 4
- 229960001225 rifampicin Drugs 0.000 description 4
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 4
- 229960004089 tigecycline Drugs 0.000 description 4
- FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 description 4
- 229960000707 tobramycin Drugs 0.000 description 4
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 4
- KGPGQDLTDHGEGT-JCIKCJKQSA-N zeven Chemical compound C=1C([C@@H]2C(=O)N[C@H](C(N[C@H](C3=CC(O)=C4)C(=O)NCCCN(C)C)=O)[C@H](O)C5=CC=C(C(=C5)Cl)OC=5C=C6C=C(C=5O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@H](O5)C(O)=O)NC(=O)CCCCCCCCC(C)C)OC5=CC=C(C=C5)C[C@@H]5C(=O)N[C@H](C(N[C@H]6C(=O)N2)=O)C=2C(Cl)=C(O)C=C(C=2)OC=2C(O)=CC=C(C=2)[C@H](C(N5)=O)NC)=CC=C(O)C=1C3=C4O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O KGPGQDLTDHGEGT-JCIKCJKQSA-N 0.000 description 4
- 206010031252 Osteomyelitis Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 206010060968 Arthritis infective Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004439 collateral ligament Anatomy 0.000 description 2
- 210000003709 heart valve Anatomy 0.000 description 2
- 108090000531 Amidohydrolases Proteins 0.000 description 1
- 102000004092 Amidohydrolases Human genes 0.000 description 1
- 206010005940 Bone and joint infections Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000012817 gel-diffusion technique Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 210000002967 posterior cruciate ligament Anatomy 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000000513 rotator cuff Anatomy 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- XFALPSLJIHVRKE-GFCCVEGCSA-N tedizolid Chemical compound CN1N=NC(C=2N=CC(=CC=2)C=2C(=CC(=CC=2)N2C(O[C@@H](CO)C2)=O)F)=N1 XFALPSLJIHVRKE-GFCCVEGCSA-N 0.000 description 1
- 229960003879 tedizolid Drugs 0.000 description 1
- 229960005240 telavancin Drugs 0.000 description 1
- ONUMZHGUFYIKPM-MXNFEBESSA-N telavancin Chemical compound O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O ONUMZHGUFYIKPM-MXNFEBESSA-N 0.000 description 1
- 108010089019 telavancin Proteins 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915953P | 2013-12-13 | 2013-12-13 | |
| US61/915,953 | 2013-12-13 | ||
| PCT/US2014/070337 WO2015089502A2 (en) | 2013-12-13 | 2014-12-15 | Passive immunization for staphylococcus infections |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019096593A Division JP6735879B2 (ja) | 2013-12-13 | 2019-05-23 | ブドウ球菌感染に対する受動免疫 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017504586A JP2017504586A (ja) | 2017-02-09 |
| JP2017504586A5 true JP2017504586A5 (enExample) | 2017-11-30 |
| JP6533226B2 JP6533226B2 (ja) | 2019-06-19 |
Family
ID=53370699
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016538593A Active JP6533226B2 (ja) | 2013-12-13 | 2014-12-15 | ブドウ球菌感染に対する受動免疫 |
| JP2019096593A Active JP6735879B2 (ja) | 2013-12-13 | 2019-05-23 | ブドウ球菌感染に対する受動免疫 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019096593A Active JP6735879B2 (ja) | 2013-12-13 | 2019-05-23 | ブドウ球菌感染に対する受動免疫 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10100127B2 (enExample) |
| EP (1) | EP3079720B1 (enExample) |
| JP (2) | JP6533226B2 (enExample) |
| KR (1) | KR102318139B1 (enExample) |
| CN (1) | CN105873609B (enExample) |
| AU (1) | AU2014361821B2 (enExample) |
| BR (1) | BR112016013514B1 (enExample) |
| CA (1) | CA2931001C (enExample) |
| ES (2) | ES2754209T3 (enExample) |
| WO (1) | WO2015089502A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2663579T3 (en) | 2011-01-14 | 2017-07-31 | Univ California | THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF |
| WO2017023863A1 (en) | 2015-07-31 | 2017-02-09 | Research Institute At Nationwide Children's Hospital | Peptides and antibodies for the removal of biofilms |
| WO2017066719A2 (en) | 2015-10-14 | 2017-04-20 | Research Institute At Nationwide Children's Hospital | Hu specific interfering agents |
| EP3565834B1 (en) * | 2017-01-04 | 2025-10-22 | The Research Institute at Nationwide Children's Hospital | Antibody fragments for the treatment of biofilm-related disorders |
| KR102335573B1 (ko) * | 2017-03-31 | 2021-12-06 | 아셀, 인크. | 세균 감염 환자를 보호 및 치료하는데 유용한 살균성 또는 정균성 특성을 갖는 세포외기질 조성물 |
| WO2021007260A2 (en) | 2019-07-08 | 2021-01-14 | Research Institute At Nationwide Children's Hospital | Antibody compositions for disrupting biofilms |
| CA3204730A1 (en) * | 2021-01-15 | 2022-07-21 | Gowrishankar MUTHUKRISHNAN | Staphylococcus aureus antigen-based nucleic acid vaccines |
| EP4108197A1 (en) | 2021-06-24 | 2022-12-28 | Gradient Denervation Technologies | Systems for treating tissue |
| CN119998318A (zh) * | 2022-04-08 | 2025-05-13 | D2M生物治疗有限公司 | 抗mica/b抗体及其用途 |
| CN115925947B (zh) * | 2022-09-27 | 2023-08-22 | 上海百英生物科技股份有限公司 | 一种亲和力成熟方法及抗人pd-l1单域抗体的亲和力成熟 |
| CN120425066B (zh) * | 2025-05-06 | 2025-10-28 | 中国农业科学院北京畜牧兽医研究所 | 一种与羊种布鲁氏菌复方新诺明耐药性相关的分子标记及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4237224A (en) | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6596509B1 (en) | 1998-07-10 | 2003-07-22 | Cornell Research Foundation, Inc. | Recombinant constructs and systems for secretion of proteins via type III secretion systems |
| FR2871237B1 (fr) | 2004-06-08 | 2011-03-11 | Abag | Nouveaux polypeptides pour la mise en evidence in vitro et la prevention des infections staphylococciques sur protheses articulaires et autres materiels etrangers implantes |
| EP2893938B1 (en) | 2004-09-22 | 2019-03-06 | GlaxoSmithKline Biologicals SA | Immunogenic composition for use in vaccination against Staphylococcei |
| DK2027155T3 (en) | 2006-06-06 | 2016-05-09 | Crucell Holland Bv | HUMAN BINDING MOLECULES with killer activity against staphylococci and uses thereof |
| KR101503937B1 (ko) * | 2006-12-08 | 2015-03-18 | 렉시컨 파마슈티컬스 인코퍼레이티드 | Ａｎｇｐｔｌ３ 에 대한 단일클론 항체 |
| US8101190B2 (en) | 2009-03-03 | 2012-01-24 | Ingen Biosciences | Method for diagnosing staphylococcal infections |
| ES2565377T3 (es) | 2009-04-14 | 2016-04-04 | Glaxosmithkline Biologicals Sa | Composiciones para inmunización contra Staphylococcus aureus |
| JP2013508287A (ja) * | 2009-10-14 | 2013-03-07 | ヤンセン バイオテツク，インコーポレーテツド | 抗体を親和性成熟する方法 |
| JP6038777B2 (ja) | 2010-05-03 | 2016-12-07 | ユニバーシティー オブ ロチェスター | 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）感染のための抗グルコサミニダーゼ受動免疫化 |
| CN101979089A (zh) * | 2010-11-17 | 2011-02-23 | 赤峰博恩药业有限公司 | 奶牛金黄色葡萄球菌乳房炎灭活疫苗及其制备方法 |
| CA2853943C (en) | 2011-11-02 | 2015-12-08 | University Of Rochester | Anti-glucosaminidase passive immunization for staphylococcus aureus infections |
| CN102890153A (zh) * | 2012-05-24 | 2013-01-23 | 天津兰瑞生物技术有限公司 | 脂磷壁酸elisa检测试剂盒及其制备技术 |
-
2014
- 2014-12-12 BR BR112016013514-8A patent/BR112016013514B1/pt active IP Right Grant
- 2014-12-12 ES ES14869474T patent/ES2754209T3/es active Active
- 2014-12-15 EP EP14870387.9A patent/EP3079720B1/en active Active
- 2014-12-15 AU AU2014361821A patent/AU2014361821B2/en active Active
- 2014-12-15 JP JP2016538593A patent/JP6533226B2/ja active Active
- 2014-12-15 CN CN201480067873.2A patent/CN105873609B/zh active Active
- 2014-12-15 ES ES14870387T patent/ES2822590T3/es active Active
- 2014-12-15 US US15/104,104 patent/US10100127B2/en active Active
- 2014-12-15 WO PCT/US2014/070337 patent/WO2015089502A2/en not_active Ceased
- 2014-12-15 KR KR1020167015659A patent/KR102318139B1/ko active Active
- 2014-12-15 CA CA2931001A patent/CA2931001C/en active Active
-
2018
- 2018-10-15 US US16/160,880 patent/US10577431B2/en active Active
-
2019
- 2019-05-23 JP JP2019096593A patent/JP6735879B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017504586A5 (enExample) | ||
| JP6735879B2 (ja) | ブドウ球菌感染に対する受動免疫 | |
| JP2013533210A5 (enExample) | ||
| Simon et al. | Immediate reconstruction of the mandible after resection for aggressive odontogenic tumours: a cohort study | |
| JP6227092B2 (ja) | 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）感染のための抗グルコサミニダーゼ受動免疫化 | |
| Aslam et al. | Risk factors for subsequent diagnosis of prosthetic joint infection | |
| JP2015517496A (ja) | バイオフィルム形成を防止する方法 | |
| WO2022174009A1 (en) | Antibodies that bind glucosaminidase and uses thereof | |
| Kojima et al. | III–1 Vertical Distraction Osteogenesis of a Reconstructed Mandible with a Free Non-Vascularized Iliac Bone Garft Combined with LIPUS Treatment: A Case Report | |
| WO2025106896A1 (en) | Coating of medical and implant biomaterials with an anti-biofilm agent to prevent and treat infection | |
| Cajas-Monson et al. | A 73-year-old woman with delayed intra-abdominal and systemic sepsis following complicated aortobifemoral bypass | |
| Arai et al. | IV–3 treatment-targeting based on ultrasonographic examination can improve LIPUS treatment results in delayed union | |
| EP2847216A1 (en) | Methods for preventing biofilm formation | |
| Gacon et al. | Infected total knee replacements | |
| Herbert | Surgical debridement with early skin grafting in the management of a complex diabetic foot wound | |
| Nagura et al. | I–4 The Effect of Low-Intensity Pulsed Ultrasound (LIPUS) on Human Rotator Cuff Derived Cells | |
| Fattouh et al. | COMPARISON OF DIFFERENT SURGICAL PROTOCOLS IN MANAGEMENT OF MEDICATION-RELATED OSTEONECROSIS OF THE JAW USING PLATELET-RICH FIBRIN AND BONE MORPHOGENETIC PROTEIN-2 | |
| Winkler | Treatment of Orthopedic Infections: Addressing the Biofilm Issue | |
| Uchiyama et al. | IV–2 A Femoral Targeting Method Using Ultrasonography for Low-Intensity Pulsed Ultrasound (LIPUS) Treatment After Intramedullary Nailing | |
| Hidaka et al. | I–3 Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ): Prevention by Low-Intensity Pulsed Ultrasound (LIPUS) in a Rat Model | |
| Nomura et al. | II–3 Low-Intensity Pulsed Ultrasound (LIPUS) Therapy for Hip Fracture | |
| Matsumoto et al. | III–4 Treatment with Low-Intensity Pulsed Ultrasound (LIPUS) for Open Fracture and Comminuted Fracture | |
| Tomiyama et al. | II–1 The Effect of Low-Intensity Pulsed Ultrasound (LIPUS) on Nonunion After Replantation of Upper Extremities | |
| Soffiatti | Rationale of Nail Antibiotic Clothing and “in vivo” Animal Study | |
| HK1230085A1 (en) | Passive immunization for staphylococcus infections |